Simvastatin Improves Diabetes-Induced Coronary Endothelial Dysfunction
Open Access
- 1 October 2006
- journal article
- Published by Elsevier in The Journal of Pharmacology and Experimental Therapeutics
- Vol. 319 (1) , 386-395
- https://doi.org/10.1124/jpet.106.106823
Abstract
3-Hydroxy-3-methylglutaryl CoA reductase inhibitors decrease cardiovascular morbidity in diabetic patients, but the mechanism is unclear. We studied the actions of simvastatin (SIM) in enhancing NO bioavailability and reducing oxidative stress in coronary vessels from diabetic rats and in rat coronary artery endothelial cells (RCAEC) exposed to high glucose. Coronary arteries isolated from diabetic rats showed decreases in acetylcholine (ACh)-mediated maximal relaxation from 81.0 ± 4.5% in controls to 43.5 ± 7.6% at 4 weeks and 22.3 ± 0.6% at 10 weeks of diabetes. This effect was associated with oxidative stress in coronary vessels as shown by dichlorofluorescein (DCF) imaging and nitrotyrosine labeling. Diabetes also reduced trans-coronary uptake of [3H]l-arginine. Supplemental l-arginine (50 mg/kg/day p.o.) did not improve coronary vasorelaxation to ACh. However, SIM treatment (5 mg/kg/day subcutaneously) improved maximal ACh relaxation to 65.8 ± 5.1% at 4 weeks and 47.1 ± 3.9% at 10 weeks. Coronary arteries from rats treated with both SIM and l-arginine demonstrated the same maximal relaxation to ACh (66.1 ± 3%) as SIM alone. Mevalonate and l-NAME (Nω-nitro-l-arginine methyl ester hydrochloride) inhibited the response to ACh in SIM-treated diabetic rats. Coronary arteries from all groups relaxed similarly to sodium nitroprusside. SIM increased endothelial NO synthase protein levels and blocked diabetes-induced increases in DCF and nitrotyrosine labeling in diabetic coronary vessels. SIM treatment restored normal NO levels in media from high-glucose-treated RCAEC and plasma of diabetic rat. Treatment with SIM or the NADPH oxidase inhibitor apocynin also blocked high-glucose-induced increases in reactive oxygen species and superoxide formation in RCAEC. Taken together, these data suggest that SIM improves diabetes-induced coronary dysfunction by reducing oxidative stress and increasing NO bioavailability.Keywords
This publication has 37 references indexed in Scilit:
- Effects of Chronic Administration of Fruit Extract (Citrus unshiu MARC) on Endothelial Dysfunction in Streptozotocin-Induced Diabetic RatsBiological & Pharmaceutical Bulletin, 2005
- High Glucose-Induced Tyrosine Nitration in Endothelial Cells: Role of eNOS Uncoupling and Aldose Reductase ActivationInvestigative Opthalmology & Visual Science, 2003
- Direct in vivo evidence of a vascular statin: a single dose of cerivastatin rapidly increases vascular endothelial responsiveness in healthy normocholesterolaemic subjectsBritish Journal of Clinical Pharmacology, 2002
- The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals.Nature Medicine, 2000
- Direct Vascular Effects of HMG-CoA Reductase InhibitorsTrends in Cardiovascular Medicine, 2000
- Can nitric oxide production be modulated by altering L-arginine levels?Critical Care Medicine, 1999
- Oxidation of Tetrahydrobiopterin by Peroxynitrite: Implications for Vascular Endothelial FunctionBiochemical and Biophysical Research Communications, 1999
- Prevention of Cardiovascular Events and Death with Pravastatin in Patients with Coronary Heart Disease and a Broad Range of Initial Cholesterol LevelsNew England Journal of Medicine, 1998
- Coronary Flow Reserve Is Reduced in Young Men With IDDMDiabetes, 1998
- Amelioration by L-Arginine of a Dysfunctional Arginine/Nitric Oxide Pathway in Diabetic EndotheliumJournal of Cardiovascular Pharmacology, 1995